10-Q: Sagimet Q2: Denifanstat Advances Amid Rising Losses

Sagimet Biosciences reports increased losses and cash burn in Q2 2025, alongside significant clinical progress for denifanstat in MASH and acne, and the initiation of a new Phase 1 trial for TVB-3567.

Summary

• Net loss for the three months ended June 30, 2025, increased to $10.386 million from $8.118 million in the prior year period, a 28% increase.
• Net loss for the six months ended June 30, 2025, increased to $28.562 million from $14.747 million in the prior year period, a 94% increase.
• Research and development expenses increased by $0.9 million (15%) for the three months and $11.0 million (95%) for the six months ended June 30, 2025, primarily due to increased clinical trial costs for denifanstat in MASH and TVB-3567.
• General and administrative expenses increased by $0.4 million (9%) for the three months and $1.4 million (18%) for the six months ended June 30, 2025, driven by personnel costs and professional fees.
• Cash, cash equivalents, and marketable securities totaled $135.5 million as of June 30, 2025, down from $158.1 million at December 31, 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, was $23.637 million, compared to $11.842 million for the same period in 2024.
• Denifanstat received Breakthrough Therapy designation from the FDA for non-cirrhotic MASH with moderate to advanced liver fibrosis (F2-F3).
• Successful end-of-Phase 2 interactions with the FDA support advancement of denifanstat into Phase 3 clinical trials for MASH.
• License partner Ascletis BioScience Co. Ltd. announced denifanstat met all primary and secondary endpoints in its Phase 3 trial for moderate to severe acne vulgaris in China.
• A first-in-human Phase 1 clinical trial for TVB-3567, a second FASN inhibitor for acne, was initiated in June 2025.

Sentiment

Score: 7

Explanation: Despite significant and increasing financial losses, the company has achieved substantial clinical progress with its lead drug candidate, denifanstat, including Breakthrough Therapy designation and positive Phase 3 results from a partner. The initiation of a new Phase 1 trial for TVB-3567 further strengthens the pipeline. While cash burn is high, this is typical for a clinical-stage biotech making significant R&D investments, and the clinical advancements de-risk future potential.

Positives

• Denifanstat successfully completed its Phase 2b FASCINATE-2 clinical trial in MASH, meeting both primary and multiple secondary endpoints with statistical significance.
• The FDA granted Breakthrough Therapy designation to denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (F2-F3), indicating potential for substantial improvement over existing therapies.
• Successful end-of-Phase 2 interactions with the FDA support the advancement of denifanstat into Phase 3 clinical trials for MASH.
• License partner Ascletis BioScience Co. Ltd. announced positive Phase 3 trial results for denifanstat in moderate to severe acne vulgaris in China, meeting all primary and secondary endpoints.
• Denifanstat demonstrated anti-fibrotic activity in MASH, including in patients with advanced fibrosis, with statistically significant differences in fibrosis improvement and progression to cirrhosis.
• Denifanstat showed a statistically significant increase in polyunsaturated triglycerides, suggesting potential cardiovascular benefits.
• The Investigational New Drug (IND) application for TVB-3567, a second FASN inhibitor, was cleared in March 2025, and a first-in-human Phase 1 clinical trial for acne was initiated in June 2025.
• Preclinical data showed a synergistic effect of a FASN inhibitor (TVB-3664, surrogate for denifanstat) and resmetirom on liver disease markers in mouse models of MASH.

Negatives

• Net loss significantly increased by 28% for the three months and 94% for the six months ended June 30, 2025, compared to the prior year periods.
• Research and development expenses increased substantially, reflecting higher costs associated with advancing drug candidates.
• General and administrative expenses also increased due to headcount growth and public company operating costs.
• Cash, cash equivalents, and marketable securities decreased to $135.5 million as of June 30, 2025, from $158.1 million at December 31, 2024, indicating a significant cash burn.
• Net cash used in operating activities more than doubled for the six months ended June 30, 2025, compared to the same period in 2024.
• The company will require substantial additional capital to fund its research and development and ongoing operating expenses for the foreseeable future.

Risks

• The company will require substantial additional capital to fund its research and development and ongoing operating expenses.
• The company has incurred recurring losses and negative cash flows from operations since inception and expects this to continue for the foreseeable future.
• The ability to raise additional funds may be adversely impacted by macroeconomic conditions, disruptions, and volatility in credit and financial markets, and geopolitical turmoil.
• Inability to obtain adequate financing could force delays, reductions in scope, or elimination of research and development programs.
• Difficulties in obtaining regulatory approval or complying with conditions imposed by regulatory authorities for clinical trials.
• Delays in reaching or failing to reach agreement on acceptable terms with contract research organizations (CROs), contract manufacturing organizations (CMOs), and trial sites.
• Insufficient supply of drug candidates or other materials necessary for clinical trials.
• Slow enrollment and retention rates of subjects in clinical trials.
• Governmental or regulatory delays and changes in regulatory requirements, policy, and guidelines.
• Serious and unexpected drug-related side effects related to drug candidates being tested.
• Lack of adequate funding to continue clinical trials.
• Failure of third-party contractors or investigators to comply with regulatory requirements or meet contractual obligations in a timely manner.

Future Outlook

The company plans to initiate a Phase 1 clinical trial in the second half of 2025 to evaluate the pharmacokinetics and tolerability of a combination of denifanstat and resmetirom, with anticipated data readout in the first half of 2026. They anticipate building on positive outcomes from this trial to develop a combination product for MASH patients. The company's license partner, Ascletis, plans to submit denifanstat for approval to the China National Medical Products Administration for the treatment of moderate to severe acne. The company expects research and development expenses to increase substantially as they advance drug candidates and expand their pipeline, and general and administrative expenses to increase with headcount and corporate infrastructure growth. They do not expect revenue from product sales until regulatory approval, which is years away, and anticipate financing future cash needs through equity, debt, or collaborations.

Management Comments

• We expect our research and development expenses to increase substantially for the foreseeable future as we advance our drug candidates into and through preclinical studies and clinical trials, pursue regulatory approval and expand our pipeline.
• We expect our general and administrative expenses to increase for the foreseeable future as we increase our headcount and continue to grow our corporate infrastructure.
• We anticipate that we will incur increased expenses as a result of operating as a public company.
• We do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our drug candidates, which we expect will take a number of years, if ever.
• Based on our current business plans, we believe that our existing cash, cash equivalents, and marketable securities as of June 30, 2025, will be sufficient for us to fund our operating expenses for at least the next 12 months from the issuance of this Quarterly Report.

Industry Context

The company operates in the clinical-stage biopharmaceutical sector, specializing in fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases. The MASH (formerly NASH) market is a key focus, with resmetirom (Rezdiffra) currently being the only FDA-approved product. The company's strategy to explore a combination of denifanstat with resmetirom positions it to potentially compete or complement the existing market leader. The expansion into acne and glioblastoma multiforme (GBM) indicates a diversified pipeline targeting areas where FASN dysregulation plays a role, aligning with broader industry trends of exploring novel mechanisms for complex diseases.

Comparison to Industry Standards

• Denifanstat's Breakthrough Therapy designation for MASH aligns it with other promising therapies that have demonstrated substantial improvement over existing treatments, such as resmetirom (Rezdiffra), which is currently the only FDA-approved product for MASH.
• Preclinical data showing synergistic activity of a FASN inhibitor (TVB-3664, a surrogate for denifanstat) when combined with resmetirom, with 80% histological improvement (NAS 2 points) compared to 33% for FASN inhibitor monotherapy and 25% for resmetirom monotherapy, suggests a potentially superior efficacy profile compared to single-agent approaches in the MASH treatment landscape.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings as of June 30, 2025.

Related Party Transactions

• Jinzi J. Wu, Ph.D., a former member of the company's board of directors (until June 2024), founded and serves as the chief executive officer of Ascletis, Gannex, and Ascletis Pharma. Ascletis is the company's license partner for denifanstat in Greater China.
• During the six months ended June 30, 2024, the company recognized $0.1 million of expenses under the Ascletis license agreement, including manufacturing services fees.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises (equity offerings) but benefit from significant clinical advancements that could increase long-term value.
• Employees benefit from continued employment, updated employment agreements with clear compensation terms, and expanded equity incentive and purchase plans.
• Patients and healthcare providers could benefit from new treatment options for MASH, acne, and glioblastoma if denifanstat and TVB-3567 successfully complete development and gain regulatory approval.
• Creditors and suppliers may face increased business volume due to expanded research and development activities, but also bear risk associated with the company's ongoing losses and need for additional financing.

Next Steps

• Explore funding alternatives for Phase 3 clinical trials for denifanstat in MASH.
• Initiate a Phase 1 clinical trial to evaluate the pharmacokinetics and tolerability of a combination of denifanstat and resmetirom in the second half of 2025.
• Anticipate data readout for the denifanstat and resmetirom combination Phase 1 trial in the first half of 2026.
• Ascletis BioScience Co. Ltd. plans to submit denifanstat for approval to the China National Medical Products Administration for the treatment of moderate to severe acne.

Key Dates

Recommendation

While the company has achieved significant clinical milestones, including Breakthrough Therapy designation for denifanstat in MASH and positive Phase 3 results for acne from its partner, these advancements come with a substantial and increasing financial burn. The company's net loss nearly doubled year-over-year for the six-month period, and cash reserves are declining, necessitating future capital raises. For a seasoned investor, the strong clinical progress is a positive signal for long-term potential, but the escalating financial needs and current unprofitability suggest a 'hold' position, awaiting clearer paths to commercialization or further de-risking of the pipeline before a more aggressive stance.

Keywords

Biopharmaceutical, FASN inhibitor, MASH, NASH, Acne, Glioblastoma, Denifanstat, TVB-3567, Clinical-stage, Drug development, Clinical trials, Breakthrough Therapy, SEC filing, Quarterly report